Journal
STEM CELL RESEARCH
Volume 49, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.scr.2020.102073
Keywords
-
Funding
- Regenerative Medicine (the Program for Intractable Disease Research Utilizing Disease-specific iPS Cells)
- Regenerative Medicine (Acceleration Program for Intractable Diseases Research Utilizing Disease-specific iPS Cells)
- Practical Research Project for Rare/Intractable Diseases from Japan Agency for Medical Research and development, AMED [16ek0109013h0003, 16ek0109158h0002, 16bm0609003h0005, 17bm0804003h0001, 18bm0804003h0002, 19bm0804003h0003, 20bm0804003h0104, 20bm0804023h0001]
- MEXT [8007, 19H05428, 17H05704]
- JSPS [20K06914]
- Naito Foundation
- GSK Japan Research Grant 2015
- Science Research Promotion Fund of The Promotion and Mutual Aid Corporation for Private Schools of Japan
- Kitasato University School of Allied Health Sciences
- Graduate School of Medical Sciences, Kitasato University
- Grants-in-Aid for Scientific Research [20K06914, 19H05428, 17H05704] Funding Source: KAKEN
Ask authors/readers for more resources
Leucine-rich repeat kinase 2 (LRRK2) is the causal gene of the autosomal dominant hereditary form of Parkinson's disease (PD), PARK8. We have previously reported that induced pluripotent stem cells (iPSCs) from a PARK8 patient with I2020T LRRK2 mutation replicated to some extent the pathologic phenotype evident in the brain of PD patients. In the present study, we generated gene-corrected iPSCs line, KEIUi001-A, using TALEN-mediated genome editing. KEIUi001-A retained a normal karyotype and pluripotency, i.e. the capacity to differentiate into cell types of the three germ layers. This iPSCs will be valuable for clarifying various aspects of LRRK2-related pathology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
